siRNA


Also found in: Acronyms, Wikipedia.

siRNA

siRNA

short, interfering ribonucleic acid.

siRNA

abbrev. SHORT INTERFERING RNA
References in periodicals archive ?
The combined technologies of Dharmacon and amaxa enable us to broaden the application of siRNA so that it can be introduced into difficult cell lines, and with the 96-well Shuttle system researchers can also accomplish this in high throughput," said William S.
CONTACT: Greg Weaver, SVP & CFO of Sirna Therapeutics, Inc.
By tackling the need for standards early on, RNAi Global is accelerating the way we will be able to work with genome-wide siRNA libraries, which in turn has the potential to accelerate disease and drug research.
CONTACT: Greg Weaver, SVP & Chief Financial Officer of Sirna Therapeutics, Inc.
Translational research is already affecting all phases of drug development, and we believe the novel capabilities provided by genome-wide siRNA libraries will help advance our translational research further and faster," said Louis Weiner, M.
Reason to buy The siRNA report covers complete Pipeline intelligence and understanding over therapeutics development for siRNA.
Altogen Labs is unique in that it offers a comprehensive host of RNAi services (among many other preclinical biology lab services) including RNAi gene targeting, siRNA synthesis, functional in vitro validation via qPCR and Western Blot, siRNA encapsulation, in vivo siRNA protection and tissue-targeted delivery.
As indicated earlier, the siRNA approach can only be used if the exact DNA sequence of the target gene (and thus of its mRNA) is known, so that the corresponding siRNA molecules can be created in the laboratory.
RNAi-based therapeutics selectively catalyze the destruction of the RNA transcribed from an individual gene, enabling what Sirna describes as "an entirely novel approach to discovering drugs" with the potential to produce "highly specific, potent, and long-lasting effects.
Sirna believes that its issued and pending patents in siRNA design, chemistry, synthesis, delivery and manufacturing together with its target patents and microRNA patents, give the company a dominant intellectual property portfolio in the field of RNAi-based therapeutics.
The siRNA assay portfolio comprises two types of siRNA products from QIAGEN, the HP GenomeWide and the HP Validated siRNAs.
According to Nassim Usman, chief operating officer and senior vice president of Sirna Therapeutics in Boulder, Colorado, there is ample precedent for this opinion.